Seres Therapeutics Inc
NASDAQ:MCRB

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
NASDAQ:MCRB
Watchlist
Price: 16.69 USD -1.01% Market Closed
Market Cap: 145.7m USD

EV/EBITDA
Enterprise Value to EBITDA

-1
Current
-1.7
Median
5.5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1
=
Enterprise Value
113.6m USD
/
EBITDA
-112.6m USD
EBITDA Growth EV/EBITDA to Growth
US
Seres Therapeutics Inc
NASDAQ:MCRB
Average EV/EBITDA: 16.3
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 553 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.4
17%
1.2
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -460.6 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.4
2-Years Forward
EV/EBITDA
-1.3
3-Years Forward
EV/EBITDA
-1.3